EUVIMEDFaigh amach EUVIMED
Open access · CC BY-NC-ND 4.0

Draw on advantages and avoid disadvantages: CT-derived individualized radiomic signature for predicting chemo-radiotherapy sensitivity in unresectable advanced non-small cell lung cancer

Liping Yang, Mengyue Li, Yixin Liu, Zhiyun Jiang, Shichuan Xu, Hongchao Ding, Xing Gao, Shilong Liu, Lishuang Qi, Kezheng Wang

Journal of Cancer Research and Clinical Oncology · 2024

DOI: 10.1007/s00432-024-05971-4 ↗

At a glance

Journal article in Journal of Cancer Research and Clinical Oncology, 2024. Written by Liping Yang and 9 co-authors. Institution: PET-CT/MR Department, Harbin Medical University Cancer Hospital, Harbin, 150001, People's Republic of China. Major MEDLINE topics: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Chemoradiotherapy, Tomography, X-Ray Computed. Cited 2 times so far (Crossref); 28 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Hai Yan Fund of The Third Affiliated Hospital of Harbin Medical University, National Natural Science Foundation of China, National Undergraduate Innovation and Entrepreneurship Training Program.

AchoimreSubjectsSonraí leabharliostaCiteRelated studies

Abstract (original language)

BACKGROUND: Presently, the options of concurrent chemo-radiotherapy (CCR) in patients with locally advanced non-small cell lung cancer (LA-NSCLC) are controversial and there is no reliable prediction tool to stratify poor- and good-responders. Although radiomic analysis has provided new opportunities for personalized medicine in oncological practice, the repeatability and reproducibility of radiomic features are critical challenges that hinder their widespread clinical adoption. This study aimed to develop a qualitative radiomic signature based on the within-sample rank of radiomics features, and to use this novel method to predict CCR sensitivity in LA-NSCLC, avoiding the variability of quantitative signatures to multicenter effect. METHODS: We retrospectively analyzed 125 patients with stage III NSCLC who received treatment from our hospital. Radiomic features were extracted from pretreatment plain CT scans and constructed as feature pairs based on their within-sample rank. Fisher and univariate Cox analyses were performed to select feature pairs significantly associated with patients' overall survival (OS). NSCLC-Radiomic (R422) cohort including 104 NSCLC patients was used as an independent testing cohort. NSCLC-Radiogenomic (RG211) cohort with matched RNA sequencing profiles, was used for functional enrichment analysis to reveal the underlying biological mechanism reflected by the signature. RESULTS: A qualitative signature, consisting of 15 radiomic feature pairs (termed as 15-RiFPS), was developed based on the Genetic Algorithm, which could optimally distinguish responder from non-responder with significantly improved OS if they received CCR treatment (log-rank P = 0.0009, HR = 13.79, 95% CIs 1.83-104.1). The performance of 15-RiFPS was validated in an independent public cohort (log-rank P = 0.0037, HR = 2.40, 95% CIs 1.30-4.40). Furthermore, the transcriptomic analyses provided biological pathways ('glutathione metabolic process', 'cellular oxidant detoxification') underlying the signature. CONCLUSIONS: We developed a CT-derived 15-RiFPS, which could potentially help predict individualized therapeutic benefit of CCR in patients with LA-NSCLC. Additionally, we investigated the underlying intra-tumoral biological characteristics behind 15-RiFPS which would accelerate its clinical application. This approach could be applied to a wider range of treatments and cancer types.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsChemoradiotherapyTomography, X-Ray ComputedPrecision MedicineHumansFemaleMaleRetrospective StudiesMiddle AgedAgedAdultAged, 80 and overPrognosisRadiomics

Author keywords

Bioinformatic analysesConcurrent chemo-radiotherapyNon-small cell lung cancerQualitativeRadiomics

Authors and institutions

  • PET-CT/MR Department, Harbin Medical University Cancer Hospital, Harbin, 150001, People's Republic of China.
  • College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150001, People's Republic of China.
  • Department of Equipment, The Second Hospital of Harbin, Harbin, People's Republic of China.
  • Department of Physical Diagnosis, Heilongjiang Provincial Hospital, Harbin, People's Republic of China.
  • Department of Thoracic Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, 150001, People's Republic of China. liushilong1984@hrbmu.edu.cn.
  • College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150001, People's Republic of China. qilishuang7@ems.hrbmu.edu.cn.

Funding

  • Hai Yan Fund of The Third Affiliated Hospital of Harbin Medical University
  • National Natural Science Foundation of China
  • National Undergraduate Innovation and Entrepreneurship Training Program
  • Provincial Key Research and Development Program of Heilongjiang Province

Cite

APA

Yang, L., Li, M., Liu, Y., Jiang, Z., Xu, S., Ding, H., Gao, X., Liu, S., Qi, L., & Wang, K. (2024). Draw on advantages and avoid disadvantages: CT-derived individualized radiomic signature for predicting chemo-radiotherapy sensitivity in unresectable advanced non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05971-4

Vancouver

Yang L, Li M, Liu Y, Jiang Z, Xu S, Ding H, et al. Draw on advantages and avoid disadvantages: CT-derived individualized radiomic signature for predicting chemo-radiotherapy sensitivity in unresectable advanced non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05971-4

BibTeX
@article{Yang2024,
  author = {Yang, Liping and Li, Mengyue and Liu, Yixin and Jiang, Zhiyun and Xu, Shichuan and Ding, Hongchao and Gao, Xing and Liu, Shilong and Qi, Lishuang and Wang, Kezheng},
  title = {Draw on advantages and avoid disadvantages: CT-derived individualized radiomic signature for predicting chemo-radiotherapy sensitivity in unresectable advanced non-small cell lung cancer},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  doi = {10.1007/s00432-024-05971-4}
}
Start for free →